Please assess the completion status of the following clinical trial:

Trial Title: Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient (≥ 18 years)~* patient hospitalized~* patient receives systemic antibiotic treatment~* patient contractually capable~* patient able to follow study procedures~* informed consent of patient~Exclusion Criteria:~* allergy against yeast and/or Perenterol® forte und/oder placebos containing Saccharomyces cerevisiae HANSEN CBS 5926, lactose-monohydrate, magnesium stearate, gelatine, sodium dodecyl sulfate, titan dioxide, microcrystalline cellulose.~* central venous catheter~* immunosuppression~* diarrhoea and/or chronic diarrhoea~* regular intake of Perenterol®, Perenterol® forte oder Yomogi® in the last seven days before the start of the study~* systemic antimycotic treatment~* systemic antibiotic treatment within the last 6 weeks~* no protection against conception, pregnancy, or lactation~* simultaneous participation in other clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saccharomyces boulardii (Type: ACTIVE_COMPARATOR): Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
- Microcristallin cellulose (Type: PLACEBO_COMPARATOR): Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation

Based on this trial design, predict the completion outcome and termination type (if applicable).